Q-omics provides the consensus-scored NAA50 profile across patient tissues and cancer cell-line models. NAA50 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NAA50 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, NAA50 protein abundance shows 29,940 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where NAA50 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAA50 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAA50 survival associations across molecular data types. NAA50 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAA50 RNA expression–survival associations across cancer types. High NAA50 expression shows unfavorable associations in ACC, LIHC, PAAD, LUAD and KICH, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NAA50 RNA expression.
This table summarizes NAA50 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NAA50. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAA50 shows higher tumor expression in BLCA, HNSC, LIHC, COAD, LUSC and LUAD. The BLCA box plot shows higher NAA50 RNA expression in tumor versus normal tissue (log2 FC = +1.012, t-test p < 0.001).
This table shows molecular features associated with NAA50 in patient tissues and cancer cell lines. In patient samples, NAA50 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NAA50 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
